by admin | Mar 3, 2016 | Uncategorized
Researchers have for the first time documented a case of an individual contracting HIV, a multi-drug resistant strain, while apparently adhering well to the daily regimen of Truvada as pre-exposure prophylaxis (PrEP). The scientists concluded that it is indeed... 
by admin | Mar 3, 2016 | Uncategorized
A long-acting injectable formulation of ViiV’s cabotegravir and Janssen’s Edurant (rilpivirine), dosed every four or eight weeks, is safe and generally well tolerated and suppresses HIV as well as a daily oral regimen in an ongoing trial. The companies intend to... 
by admin | Mar 3, 2016 | Uncategorized
The U.S. Food and Drug Administration has approved the single-tablet HIV treatment regimen Odefsey, which includes a new, safer version of tenofovir. The tablet is an updated version of Complera, swapping tenofovir alafenamide, or TAF, for tenofovir disoproxil... 
by admin | Jan 27, 2016 | Uncategorized
Thanks to many, many volunteers and scores of donors, we were able to end 2015 in very comfortable shape. We were able to minister to many and our financials are looking good for 2016. Between the middle of November and Christmas we were very busy with a variety of...